GLP-1 RAs significantly reduced IHA in individuals with T2DM and NAFLD (Class IV
Toppo S, Vanin S, Bosello V, Tosatto SC
doi: 10.1016/j.pmpp.2008.04.003 43 LiX.AnM.XiaZ.BaiX.WuY
Batra, N., De Souza, C., Batra, J., Raetz, A
Current allegations in the GLP-1 litigation commonly involve claims that: manufacturers failed to provide adequate warnings about delayed gastric emptying and severe gastrointestinal injury risks GLP-1 drugs may cause gastroparesis, ileus, or intestinal obstruction in certain patients patients were not properly informed of the potential side effects beyond common nausea and appetite suppression warning labels did not clearly reflect the risk of long-term digestive dysfunction some patients experienced permanent or prolonged impairment after discontinuing the medication the drugs were marketed in ways that downplayed serious adverse outcomes These allegations are not limited to Victoza, but Victoza has become part of this broader litigation because its mechanism of action overlaps with other GLP-1 medications now facing coordinated claims
Learn More CJC-1295 / Ipamorelin Benefits at SSK Longevity in Newport Beach, CA The CJC-1295 / Ipamorelin growth hormone secretagogue stack at SSK Longevity in Newport Beach delivers reliable improvements in sleep quality, recovery, lean mass preservation, and longevity-relevant outcomes
